---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-027857"
form_type: "8-K"
ticker: "MLAB"
cik: "0000724004"
company_name: "MESA LABORATORIES INC /CO/"
filed_at: "2022-11-21T23:59:59+00:00"
generated_at: "2026-06-21T15:23:29.163710+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Mesa Labs loses key customer Sema4; orders to drop starting Q3 FY2023

## Summary
- Sema4 exiting reproductive health screening; will significantly reduce consumables orders starting Q3 FY2023.
- Without Sema4, Clinical Genomics ex-COVID revenues would have been ~$56.3M vs $64.5M over prior 12 months.
- Sema4 products generated significantly higher gross profit percentage than overall Clinical Genomics business.
- Mesa has no other material revenues for expanded carrier screening with other customers.

## SEC filing metadata
- accession: 0001437749-22-027857
- form_type: 8-K
- ticker: MLAB
- cik: 0000724004
- company_name: MESA LABORATORIES INC /CO/
- filed_at: 2022-11-21T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/724004/000143774922027857/0001437749-22-027857-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/724004/000143774922027857/mlab20221121_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-027857
- JSON: https://secwatch.observer/filing/0001437749-22-027857.json
- Plain text: https://secwatch.observer/filing/0001437749-22-027857.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.